Applications of (S)-1-(4-Nitrophenyl)Ethylamine Hydrochloride in Industrial Manufacturing

Our expertise in producing (S)-1-(4-Nitrophenyl)Ethylamine Hydrochloride enables its integration into key industrial synthesis processes requiring high-purity chiral amines. Selected downstream applications below highlight how manufacturers implement this intermediate in the synthesis of value-added specialty products, illustrating regulatory adherence, formulation guidelines, process steps, and resulting end-use materials in each specific field.

1. Antidepressant Active Pharmaceutical Ingredient (API) Synthesis

Major pharmaceutical companies use this chiral amine hydrochloride as a building block in the multi-step synthesis of selective serotonin-norepinephrine reuptake inhibitors (SSNRIs). Its precise optical purity supports stereo-controlled steps that yield APIs with consistent pharmacological activity, requiring rigorous quality and impurity controls throughout the process. Manufacturing compliance is verified by batch-level traceability and alignment with global API regulations.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
• Ph. Eur. Monographs (where applicable for chiral intermediates)
• US FDA cGMP (21 CFR Parts 210/211)
• Chinese Pharmacopoeia, Part II (for export-oriented API production)

Typical usage ratio

• Common loading is 0.85–1.05 molar equivalents per key coupling step, with adjustments based on intermediate yield and enantiomeric excess required by the downstream API target.

Downstream process integration

• Introduced during enantioselective amination or amidation steps, frequently following base-catalyzed deprotection and preceding condensation with heterocyclic scaffolds in multi-kilogram batch reactors.

Final product types

• Pharmaceutical-grade SSNRI APIs such as duloxetine and derivative compounds
• Finished oral solid dosage forms (tablets, capsules) produced by formulators downstream

2. Asymmetric Catalyst Ligand Production

Fine chemical and catalyst manufacturers employ this compound as a precursor for the synthesis of chiral ligands used in metal-catalyzed asymmetric hydrogenation and transfer reactions. The material’s enantiopurity directly translates to the selectivity of derived ligands, impacting the efficacy of downstream catalytic systems. Manufacturers must document entire supply chain traceability and specification conformity for regulated catalyst shipments.

Industry compliance standards

• ISO 9001:2015 (Quality Management for Specialty Chemicals)
• REACH (EC 1907/2006 concerning registration, evaluation, and authorization of chemical substances in the EU)
• Analytical data reporting in line with ACS Inorganic Chemistry guidelines (for ligand purity verification)

Typical usage ratio

• Standard application requires 1.00–1.25 molar equivalents per desired chiral ligand unit; optimization based on ligand complexity and desired turnover frequency in final catalyst systems.

Downstream process integration

• Incorporated at the initial amination or reductive amination stage with protected or activated aromatic skeletons before metal coordination and immobilization steps in catalyst manufacture.

Final product types

• Chiral phosphine and imine ligands for catalytic hydrogenation
• Supported asymmetric catalysts for use in bulk pharmaceutical and agrochemical production

3. Chiral Resolving Agent Manufacturing for Agrochemical Intermediates

Leading agrochemical upstream producers use this compound to generate resolving agents that facilitate stereoselective separation of racemic pesticide intermediates. This enables cost-effective production of enantiomerically pure active ingredients, a requirement for compliance with international agrochemical registration and traceability rules. Formulators precisely control usage volume to maximize yield without exceeding process specification limits.

Industry compliance standards

• FAO/WHO Specifications and Evaluations for Agricultural Pesticides
• ISO 17025 Analytical Laboratory Accreditation (for chiral purity verification)
• EU Regulation (EC) No 1107/2009 for plant protection product approval

Typical usage ratio

• Addition typically ranges from 0.8–1.2 molar equivalents relative to the racemate, adjusted to achieve target enantiomeric resolution efficiency and based on downstream HPLC analytics.

Downstream process integration

• Reacted with racemic intermediates at the salt formation step; subsequent precipitation, filtration, and chiral separation performed to isolate pure stereoisomers ahead of active ingredient finishing steps.

Final product types

• Stereochemically pure agrochemical building blocks
• Registered plant protection active substances, meeting regulatory requirements in North America, EU, and APAC

4. Diagnostic Imaging Agent Intermediate Synthesis

Contract development and manufacturing organizations (CDMOs) serving medical imaging markets source this enantiomerically pure amine hydrochloride for incorporation into precursor molecules for radiolabeled diagnostics and PET agents. Purity and batch homogeneity are critical to minimizing radiolabeling side-products and impurities in the intricate synthesis routes for clinical tracers. Facilities operate under certified analytical and GMP frameworks to safeguard production quality.

Industry compliance standards

• USP General Chapter <823> (Radiopharmaceuticals for Positron Emission Tomography)
• GMP for Pharmaceuticals (PIC/S PE009)
• ICH Q3A/B (Impurity Testing for New Drug Substances and Products)

Typical usage ratio

• 0.9–1.1 molar equivalents per precursor synthesis step; fine-tuned according to downstream activity concentration, isotopic labeling efficiency, and supplier batch analysis.

Downstream process integration

• Supplied as an intermediate for nucleophilic aromatic substitution, followed by multi-stage protection-deprotection and, subsequently, isotopic labeling with fluorine-18 or carbon-11 to yield the desired imaging agent.

Final product types

• Clinical-grade PET tracer precursors (e.g., fluroalkyl derivatives)
• Radiolabeled diagnostic compounds for oncology, neurology, and cardiology imaging

5. Fluorescent Dye Intermediate Manufacturing

Specialty dye manufacturers use this hydrochloride salt in the stepwise synthesis of highly specific fluorescent markers and probes used in bioanalytical and molecular biology research. Optical activity and purity impact quantum yield and labeling precision in the final product. Downstream QC traceability and supplier-certification underpin acceptance by regulated research and diagnostics markets in the US, EU, and Asia-Pacific.

Industry compliance standards

• ISO 13485 (Medical Devices – Quality Management for Research Use Only Reagents)
• CLSI GP44 (Preparation and Quality Management of Reagents in Clinical Laboratories)
• Declaration of Conformity to RoHS (for non-toxic dye applications in devices)

Typical usage ratio

• Loading typically set at 0.95–1.10 molar equivalents, guided by purity levels of subsequent synthetic intermediates and quantum yield optimization of finished dye molecules.

Downstream process integration

• Used after initial nitro reduction and before azo coupling or amidation, forming the amine-functionalized aromatic core essential for final dye structure assembly.

Final product types

• Custom synthetic fluorescent dyes for in vitro diagnostics
• Labeled molecular biology reagents for flow cytometry, immunoassay, and imaging kits